Growth factors as treatment options for intestinal inflammation

Brian K. Dieckgraefe, Joshua R. Korzenik, Shrikant Anant

Research output: Chapter in Book/Report/Conference proceedingConference contribution

21 Scopus citations

Abstract

On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.

Original languageEnglish
Title of host publicationInflammatory Bowel Disease
Subtitle of host publicationGenetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways
PublisherBlackwell Publishing Inc.
Pages300-306
Number of pages7
ISBN (Print)1573315680, 9781573315685
DOIs
StatePublished - Jan 1 2006

Publication series

NameAnnals of the New York Academy of Sciences
Volume1072
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Keywords

  • Crohn's disease
  • Growth factors
  • Inflammatory bowel disease
  • Sargramostim

Fingerprint Dive into the research topics of 'Growth factors as treatment options for intestinal inflammation'. Together they form a unique fingerprint.

  • Cite this

    Dieckgraefe, B. K., Korzenik, J. R., & Anant, S. (2006). Growth factors as treatment options for intestinal inflammation. In Inflammatory Bowel Disease: Genetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways (pp. 300-306). (Annals of the New York Academy of Sciences; Vol. 1072). Blackwell Publishing Inc.. https://doi.org/10.1196/annals.1326.007